These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 3142712

  • 1. 3,5,3'-Triiodothyroacetic acid minimizes the pituitary thyrotrophin secretion in patients on levo-thyroxine therapy after ablative therapy for differentiated thyroid carcinoma.
    Mueller-Gaertner HW, Schneider C.
    Clin Endocrinol (Oxf); 1988 Apr; 28(4):345-51. PubMed ID: 3142712
    [Abstract] [Full Text] [Related]

  • 2. TRIAC (3,5,3'-triiodothyroacetic acid) has parallel effects at the pituitary and peripheral tissue levels in thyroid cancer patients treated with L-thyroxine.
    Mechelany C, Schlumberger M, Challeton C, Comoy E, Parmentier C.
    Clin Endocrinol (Oxf); 1991 Aug; 35(2):123-8. PubMed ID: 1934526
    [Abstract] [Full Text] [Related]

  • 3. 3,5,3'-triiodothyroacetic acid therapy for thyroid hormone resistance.
    Kunitake JM, Hartman N, Henson LC, Lieberman J, Williams DE, Wong M, Hershman JM.
    J Clin Endocrinol Metab; 1989 Aug; 69(2):461-6. PubMed ID: 2753985
    [Abstract] [Full Text] [Related]

  • 4. Comparison of the metabolic and endocrine effects of 3,5,3'-triiodothyroacetic acid and thyroxine.
    Bracco D, Morin O, Schutz Y, Liang H, Jéquier E, Burger AG.
    J Clin Endocrinol Metab; 1993 Jul; 77(1):221-8. PubMed ID: 8325946
    [Abstract] [Full Text] [Related]

  • 5. Long-lasting effects of Triac and thyroxine on the control of thyrotropin and hepatic deiodinase type I.
    Juge-Aubry CE, Morin O, Pernin AT, Liang H, Philippe J, Burger AG.
    Eur J Endocrinol; 1995 Jun; 132(6):751-8. PubMed ID: 7788017
    [Abstract] [Full Text] [Related]

  • 6. Highly sensitive determination of TSH in the follow-up of TSH-suppressive therapy of patients with differentiated thyroid cancer.
    Mann K, Saller B, Mehl U, Hörmann R, Moser E.
    Nuklearmedizin; 1988 Feb; 27(1):24-8. PubMed ID: 3368333
    [Abstract] [Full Text] [Related]

  • 7. Triac (3,5,3'-triiodothyroacetic acid) partially inhibits the thyrotropin response to synthetic thyrotropin-releasing hormone in normal and thyroidectomized hypothyroid patients.
    Medeiros-Neto G, Kallas WG, Knobel M, Cavaliere H, Mattar E.
    J Clin Endocrinol Metab; 1980 Feb; 50(2):223-5. PubMed ID: 6766460
    [Abstract] [Full Text] [Related]

  • 8. [Triiodothyroacetic acid in euthyroid goiter. New data on its mechanisms of action. Comparison with L-thyroxin].
    Pisarev MA, Brenta G, Schnitman M, Kleiman de Pisarev DL.
    Bull Acad Natl Med; 2007 Nov; 191(8):1705-15; discussion 1715. PubMed ID: 18666468
    [Abstract] [Full Text] [Related]

  • 9. Sequential changes in the pituitary thyroid axis after chronic TRH administration: effects on euthyroid and thyroxine treated female rats.
    Iglesias R, Llobera M, Montoya E.
    Acta Endocrinol (Copenh); 1985 Jun; 109(2):237-42. PubMed ID: 3925674
    [Abstract] [Full Text] [Related]

  • 10. The effects of tetraiodothyroacetic and triiodothyroacetic acids on thyroid function in euthyroid and hyperthyroid subjects.
    Burger AG, Engler D, Sakoloff C, Staeheli V.
    Acta Endocrinol (Copenh); 1979 Nov; 92(3):455-67. PubMed ID: 117664
    [Abstract] [Full Text] [Related]

  • 11. Effects of thyroid hormones (T4,T3), bromocriptine and Triac on inappropriate TSH hypersecretion.
    Salmela PI, Wide L, Juustila H, Ruokonen A.
    Clin Endocrinol (Oxf); 1988 May; 28(5):497-507. PubMed ID: 3214942
    [Abstract] [Full Text] [Related]

  • 12. Surveillance of TSH-suppressive levothyroxine treatment in thyroid cancer patients: TRH testing versus basal TSH determination by a third generation assay.
    Görges R, Saller B, Eising EG, Quadbeck B, Mann K, Bockisch A.
    Exp Clin Endocrinol Diabetes; 2002 Oct; 110(7):355-60. PubMed ID: 12397535
    [Abstract] [Full Text] [Related]

  • 13. Assessment of thyroxine suppression in thyroid carcinoma patients with a sensitive immunoradiometric TSH assay.
    Lamberg BA, Helenius T, Liewendahl K.
    Clin Endocrinol (Oxf); 1986 Sep; 25(3):259-63. PubMed ID: 3791667
    [Abstract] [Full Text] [Related]

  • 14. Triac reduces serum TSH without decreasing alpha and beta TSH messenger RNAs.
    Mirell CJ, Yanagisawa M, Hershman JM.
    Horm Metab Res; 1989 Mar; 21(3):123-6. PubMed ID: 2744717
    [Abstract] [Full Text] [Related]

  • 15. Differences in response of thyrotropin to 3,5,3'-triiodothyronine and 3,5,3'-triiodothyroacetic acid in patients with resistance to thyroid hormone.
    Ueda S, Takamatsu J, Fukata S, Tanaka K, Shimizu N, Sakata S, Yamaji T, Kuma K, Ohsawa N.
    Thyroid; 1996 Dec; 6(6):563-70. PubMed ID: 9001190
    [Abstract] [Full Text] [Related]

  • 16. Serum thyrotropin and prolactin in the syndrome of generalized resistance to thyroid hormone: responses to thyrotropin-releasing hormone stimulation and short term triiodothyronine suppression.
    Sarne DH, Sobieszczyk S, Ain KB, Refetoff S.
    J Clin Endocrinol Metab; 1990 May; 70(5):1305-11. PubMed ID: 2110573
    [Abstract] [Full Text] [Related]

  • 17. Thyrotropin-releasing hormone and thyroid hormone interactions on thyrotropin secretion in the rat: lack of inhibiting effects of small doses of triiodo-L-thyronine in the hypothyroid rat.
    García MD, Escobar del Rey F, Morreale de Escobar G.
    Endocrinology; 1976 Jan; 98(1):203-13. PubMed ID: 813987
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.